~~<i id='D510B3F2E1'><strike id='D510B3F2E1'><tt id='D510B3F2E1'><pre id='D510B3F2E1'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-09-29 08:43:13 Page View：11

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Primary care physicians play key roles in Alzheimer's management
Next article： Medical records are filled with copy

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

Medicare Advantage overpayments discussion gets experts fired up

AdobeMedicareAdvantageisarguablythemostcontroversialhealthcareprogramrightnow—asentimentthatwasbolst

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Washington mulls new rules to avert another Change Healthcare

AdobeWashingtoniscrackingdownonthetechnologyrunningbehindthescenesinhealthcarefollowingadebilitating